Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · IEX Real-Time Price · USD
1.080
+0.060 (5.88%)
At close: Jul 2, 2024, 4:00 PM
1.100
+0.020 (1.85%)
After-hours: Jul 2, 2024, 7:57 PM EDT
Cue Biopharma Stock Forecast
CUE's stock price has decreased by -69.32% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Cue Biopharma stock have an average target of 8.00, with a low estimate of 6.00 and a high estimate of 10. The average target predicts an increase of 640.74% from the current stock price of 1.08.
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 9, 2024.
Analyst Ratings
The average analyst rating for Cue Biopharma stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 4 | 4 | 4 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 6 | 6 | 6 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Maintains $8 | Strong Buy | Maintains | $8 | +640.74% | Apr 9, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $10 | Buy | Maintains | $10 | +825.93% | Apr 9, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $8 | Buy | Reiterates | $8 | +640.74% | Apr 3, 2024 |
| Jefferies | Jefferies | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +455.56% | Mar 13, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $7 → $8 | Buy | Maintains | $7 → $8 | +640.74% | Nov 6, 2023 |
Financial Forecast
Revenue This Year
10.64M
from 5.49M
Increased by 93.86%
Revenue Next Year
14.84M
from 10.64M
Increased by 39.43%
EPS This Year
-1.01
from -1.11
EPS Next Year
-1.01
from -1.01
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 18.2M | 47.3M | 36.8M | 105.2M | 353.8M |
| Avg | 10.6M | 14.8M | 19.6M | 78.4M | 245.0M |
| Low | 4.6M | 2.0M | 8.0M | 51.5M | 178.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 230.9% | 344.0% | 147.6% | 435.5% | 351.4% |
| Avg | 93.9% | 39.4% | 32.4% | 298.9% | 212.6% |
| Low | -16.1% | -81.6% | -46.1% | 161.9% | 127.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.69 | -0.49 | -0.75 | 0.13 | 2.03 |
| Avg | -1.01 | -1.01 | -1.05 | -0.26 | 1.27 |
| Low | -1.18 | -1.56 | -1.46 | -0.63 | 0.57 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.